Key result
Statin therapy reduced cardiovascular events in men (RR 0.76; 95% CI 0.70-0.81) and women (RR 0.79; 95% CI 0.69-0.90), but women did not have reductions in mortality or stroke.
Why the study?
Does statin therapy reduce cardiovascular events in women and men separately?
Meta-Analysis
Does statin therapy reduce cardiovascular events in women and men separately?
Effect estimate: RR 0.76 in men, RR 0.79 in women (95% CI 0.70-0.81 in men, 0.69-0.90 in women)
Statins reduce overall cardiovascular events in both men and women, but the benefit in women may be driven by reductions in revascularization and unstable angina rather than mortality or stroke.
Supports statin use for CV event reduction in both sexes; confirms similar relative benefit but highlights absent mortality/stroke effects in women.
OBJECTIVE: To determine the impact of statin therapy on the combined endpoint of cardiovascular events in women and men separately. RESEARCH DESIGN AND METHODS: A systematic literature search through May 2006 was conducted to identify randomized, controlled statin trials evaluating the gender specific incidence of cardiovascular events. Weighted averages were reported as relative risks (RRs) with 95% confidence intervals (CI) calculated via random-effects model. MAIN OUTCOME MEASURES: The primary outcome measured was a composite endpoint of all cardiovascular events. Secondary outcomes measured included death, myocardial infarction (MI), and stroke. RESULTS: Fifteen trials were included in this meta-analysis. Cardiovascular events were reduced in men (RR 0.76 [95% CI 0.70, 0.81]) and women (RR 0.79 [95% CI 0.69, 0.90]). Reductions in mortality, MI, and stroke predominantly contributed to the reduction in cardiovascular events in men taking statins. Women did not have a reduction in mortality or stroke, suggesting that the reductions in cardiac events may have been predominantly due to reductions in need for revascularization and/or unstable angina. CONCLUSIONS: Statins reduced the risk of cardiovascular events in men and women, but women on statins may not have reductions in mortality and stroke like their male counterparts.
No takes yet. Share an insight, caveat, or question.
Dale et al. (2007) conducted a meta-analysis in Cardiovascular events. Statin therapy vs. Control was evaluated on Composite endpoint of all cardiovascular events (RR 0.76 in men, RR 0.79 in women, 95% CI 0.70-0.81 in men, 0.69-0.90 in women). Statin therapy reduced cardiovascular events in men (RR 0.76; 95% CI 0.70-0.81) and women (RR 0.79; 95% CI 0.69-0.90), but women did not have reductions in mortality or stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: